Medivation rejects $9.3 billion purchase bid from Sanofi

The all-cash offer was turned down unanimously by Medivation's board.

By Randy Lilleston • April 29, 2016

UBS venture fund raises $471 million for early-stage cancer investments

One of the goals of the fund will be to help bridge the gap between initial drug development and later investments by large pharma.

By Nicole Gray • April 28, 2016

AbbVie buys Stemcentrx for $5.8 billion, builds cancer drug offerings

The cash-and-stock deal gives AbbVie access to Rova-T, a small cell lung cancer treatment that has shown strong early promise.

By Randy Lilleston • April 28, 2016

Sanofi pressures Medivation to take $9.3 billion bid

After the April 15 offer drew no interest, Sanofi CEO Olivier Brandicourt makes public a letter asking Medivation CEO David Hung to explain the silence.

By Ned Pagliarulo • April 28, 2016

AstraZeneca hands off Zurampic marketing rights to Ironwood for $100 million

The gout drug just won approval from the FDA in December 2015. 

By Nicole Gray • April 26, 2016

Novartis may divest $14B stake in Roche, could generate M&A funding

The company's new heart failure drug Entresto has disappointed post-launch in the U.S., putting pressure on the Swiss drugmaker. 

By Nicole Gray • April 26, 2016

With CEO Papa headed to Valeant, Perrigo faces new challenges

The Irish drugmaker scaled back earnings expectations for 2016, citing increased competition and pricing pressures. 

By Nicole Gray • April 26, 2016

Actelion denies reports of takeover

The Swiss company also reported strong growth for its new PAH drugs in the first quarter. 

By Nicole Gray • April 22, 2016

Adding to cosmetic portfolio, Allergan buys Topokine for $85 million

This is the second deal struck by the Irish company following the collapse of its mega-merger with Pfizer. 

By Ned Pagliarulo • April 22, 2016

Boosting pipeline, AbbVie inks two deals for preclinical cancer drugs

The deals, with ArgenX and CytomX, give AbbVie a foothold in immuno-oncology. 

By Nicole Gray • April 22, 2016

In $205 million deal, Recipharm buys Kemwell's US, India CDMO businesses

The Swedish contract development firm aims to gain a foothold in the US market.

By Nicole Gray • April 21, 2016

Eli Lilly cuts ties with Transition, ends diabetes drug collaboration

The drug had recently completed Phase 2 trials, demonstrating superior weight loss compared to AstraZeneca's Byetta. 

By Nicole Gray • April 19, 2016

Report: AstraZeneca considering bid for cancer biotech Medivation

Medivation reportedly rejected an offer from Sanofi last week, although the French drugmaker could look to a hostile bid. 

By Ned Pagliarulo • April 17, 2016

Swiss company Lonza Group seeking to acquire CRO Catalent: report

Lonza Group has been expanding in the U.S. recently, acquiring Arch Chemicals in 2011. 

By Ned Pagliarulo • April 14, 2016

Celgene snaps up $50 million option for select Juno CAR-T programs

The companies previously struck a 10 year, $1 billion partnership for the development of CAR-T and TCR immunotherapies. 

By Nicole Gray • April 12, 2016

CRISPR biotech Intellia strikes licensing deal with Regeneron, readies IPO

The collaboration will throw more R&D muscle behind the company, which is competing with CRISPR Therapeutics and Editas Medicine to commercialize the gene-editing technology. 

By Ned Pagliarulo • April 11, 2016

Juno aims to bring CAR-T therapy to China with new joint venture

The biotech has partnered with WuXi AppTec to launch a new cell therapy company based in Shanghai. 

By Nicole Gray • April 11, 2016

Activist hedge fund targets Depomed board

Last year Depomed fought off a takeover attempt by Horizon Pharma. Now the hedge fund Starboard Value is demanding greater representation on the company's board, alleging Depomed is restricting shareholder rights. 

By Nicole Gray • April 11, 2016

Relypsa reportedly reviewing buyout offers on renewed interest in hyperkalemia drug

AstraZeneca paid $2.7 billion to acquire competitor ZS Pharma in November 2015.

By Nicole Gray • April 8, 2016

In potential $450 million licensing deal, J&J to develop prostate cancer drug

The company is facing increased competition in the prostate cancer market from Medivation's Xtandi. 

By Nicole Gray • April 7, 2016

Allergan snaps up rights to Alzheimer's drugs in deal with Heptares

The licensing agreement was announced hours after the collapse of Allergan's $160 billion merger with Pfizer.   

By Ned Pagliarulo • April 7, 2016

After merger with Pfizer implodes, Allergan's acquisition options open up

The Irish drugmaker will get a large influx of cash when its divestment with Teva clears U.S. regulatory authorities. 

By Ned Pagliarulo • April 6, 2016

Pfizer calls off $160 billion merger with Allergan

New rules on corporate inversions issued earlier this week by the Treasury made it more difficult for the companies to proceed with the deal. 

By Ned Pagliarulo • April 6, 2016

Nimbus liver drug bought by Gilead for $400M cash plus incentives

The deal could be worth as much as $1.2 billion once milestone payments are included. 

By Nicole Gray • April 5, 2016

Price of success: Medivation reportedly hires JP Morgan to help fend off deal-hungry buyers

The company has recently been targeted by a number of Democratic lawmakers for the high price of its cancer drug Xtandi. 

By Nicole Gray • April 1, 2016